{"id":780883,"date":"2023-08-30T07:37:55","date_gmt":"2023-08-30T11:37:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/"},"modified":"2023-08-30T07:37:55","modified_gmt":"2023-08-30T11:37:55","slug":"apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/","title":{"rendered":"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., Aug.  30, 2023  (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals,\u00a0Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>Citi Annual BioPharma Conference: Fireside chat on Wednesday, September 6, 2023, at 9:40 a.m. ET<\/li>\n<li>Wells Fargo Annual Healthcare Conference 2023: Fireside chat on Friday, September 8, 2023, at 9:30 a.m. ET<\/li>\n<\/ul>\n<p>The live conference webcasts will be posted on the \u201cEvents and Presentations\u201d page of the \u201cInvestors and Media\u201d section of the company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xoSOeccp-9dFBOB8ZoPgl-RQDJKETwcKkT7PV_kR3kMshq22gq39a-dXVRZFKlcZY9zwrYjkJixa6ikRco6-wQ==\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a>. A replay of the webcasts will be available for approximately 90 days following the event.<\/p>\n<p>\n        <strong>About Apellis<\/strong><br \/>\n        <br \/>Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iRnuljZYPJvo51LYdMdsbRnew3AvYCUWyzZHr-NOB2s-HnN5va9fdfD8nDaIeOuFldUVWNE9rHNvsP0zteJ-KgkTFojxMFdsQyOAr0gfcmjun_CH6OghsvThJaKHpHHL3kesbM6knVi6wOf0_1ZVw6PVkeuHEaR_xU047-ZfEYP5UN8ttCq7MU0gnCL6SrHrXkg7XFt1YEK49UqMuFCuo4o7gtlrF-8tZIImnqsmQWYqCkb3O8txCUYPiXkpTflQQIheoaMvPRagfUYRakvFxyOLntbVT0BNcaFXsmqkN2VBv22_M73V9PiGLcWeBd8A_NK_pbLwA5aeRpvmT_Ehocy59SGtCPIX0BdQvyRFbKGprex5G-9JmD8M_nsMS3GjoyV2lFNSNBHxxNtBxo3TyA5RIbyK69z3Q9Y-qWLQjmboE6gOGcirkhGutOKoD1Lop6uOZL7SinD6ijWqn9fOCdA1NmhlL--1DbCgqD-tpghJy2KEAMNL3C658aXemib8IfuHZkwkQ1JB2aYQPXuUxDHCr1zkhBffKdpstlUUKZZ-iiWc2h7dCaFBL9gWLO9DSpF7lksSzO5cu0zgwD-VD501LGhlnquvYFzOd8dww4R5kNCggwvnqA0OAvKrB0gZ-0-rbVtWLt2rKyh_OBTGxhU0emNt0T2lN7as_VDl4O0tdZB8LDOc_4mlqk_0WD8j7aB0eOQ5X2zPhvXQucIBTGKcyz5Icj_iHGJhJopoDZidN-vZfcBtHTtQZkGzebf7zKh06tZbHsxWTiBmQ9eajl2lIXwrRBE5yRwodbFdNBRGFw2Hc2pS5wilp_MChvIDAk9QLW51DMFUtQzrdG2UrY_Vl4OT9Wo5l-dS8yPuw-EcjWBSAzEk1YrAdajLLriG5HkqKB0_hAZ5WIp0f3fKM7bVP29Hb4WYRUiHv0Kp84_BhFo5pmX6QgyA4oBGuw4zOadNj5vYz86067h6Hi8xf8Ik09XdX81f-cGV1GkQ-FA0DhiJka-avbGpKFUzXGmY0wGQXVrJ4W9A3cKae8F8EoxATOapqZVjD9BIk8_pbAB3KW7L6ZlidVdoBRDJPSnP\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/apellis.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qnkq4Y1ECSgPQDIKQU3GXJ-HXmbnTT3LSZpf6o9pzgnjA2G_3EbkU9l3ShiIUGF4mtDoKVXgfWx1Ifx7y_JxNka9m91eoFK8ZEQXAtrftycBWQQ8h1KRMCkFATHS2XBHTF1IcXFDwgtERli0wLsfuCgxWbVo11XcuFxewtObm_117s5Yog8IpBBXoQZiEaDJLB3w75isKBtrKyQ-UIb-Rv39o5VeQFEA2zw5sjb5M3bE74fZyXvWqSymGsXB9Xj4X8cQFGwCRS44uC_-J4hFVpuA9hSROYFLka3Hvu-PzUDD9umtlkz3x81ONuBexrlacQN-3ILNjzYlu66Kod2sgDF7t8B_gYNOmgSM89TM77hhOKbfFbeAI7jl57QhXN1pxy2bE0ogvihwHmC25rvBI4dd8R0_4mhEufTZW4K4udEm1B1edUEvpfRjABvfvuuMq80zR5ZtDYqUM_s6RO2e6zPfrblY5ihMTSic4o-xtYGH4HPAvMvL5BL9OZJSx-cd3UaA5fMhsnq8v9hThJR2NOX_0KT7Kv0Qg5yLhLCMZ5vD7vU2_75nEkhiuaEvQu33CgxylePKNyn1luHNpsSECnUIjDOQFHbYqczxMzERKLvHkr0B7wPVyM2nfwlDeErxVUGOdrewnabZUn_I8_rQDcHU-8lKVPz6xIKqdGqHPTfAv0m0IeK1BDKoP4SZTvfIxG0b6sLLLQjP5D_8abUvccWh7pqD2nkyN1SAYTw_XhG5AYbtGXoECgegwJ6BrKfg4969Aule50SIdvw0eMqqjcB_mEkOx2pIEwwb19VqCRjo_DbQ-XouB-mzz6tLlxyiM-xcuy-vm6KT4tj9T4LEkIktTLr9MEv_kM-NtkzSNFw=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xDQSBtpujFlrYXQW0uAzuNPoVkuvCBViQJH7gMIjqgmQ0-ZSgECyjRFYbmopATZDyTUSwCR9I8QQtUzb-aHKG5dHNmWhwLwyHxlsxzI8uIiN6yQ_2FwQVBjR8eyfpT2sA-kRDY2YDHEmEL6yVXy-rIDda20TPDNPN5WBncy_ZPnLwW0My8UEOCIZcbFHxvqbJgXBHQaFf3ScYiMBhyUav0ApjEtooseFiT48kCkPux_PpBiQjZXmrKvcEZiMl4sDnAXo5YxYsppyU6hGaq4n9WoPI5jwTDO9V1UGVuGBkuA-cZmk_QzbxEpNoKX76nYOHM32feXsMOt_nR-_pxyqCy3e0HuATOKuUaVZTr-eExHCOpGXojMEhu6cKsFIYfrSwbNJv4kD1SYHFvO3DBO-Zy8jF5TwN4EQvjQhMjMFfGdksrjvYyl6q_00xy2Tx70U2JI5iaSmvQakmpAEPCi0YZPdmA41c_M3J3j57s9-1fHmOJPrWbykx1-e1I02oh9Vw5Mu06AraZ2qZ4IBvge2v5z6zTBqasQ1-T2wlxDXPjLRfLMwaOKy1oLv7MfMoBHNlDbJuwh-P4w2fBMiDzski14Q9qyUb3_TBdDpx3b4zSvEKlQUILuRirT7402NbzUqqhy0WK4ZsVU6_qstkvdbnoJjQ5lhF90uq4Y0i4bLrbn8VVVS5j3Sf_J1Fd83nL_i\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong>\u00a0<br \/>Meredith Kaya\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l8UiFVqGQ0XUptFl_TpEMGvG6lfVHKueJbuND3sqjQNUwa6_zggJdWxWaLp3_XImqUOvDEMdH4xQQ8rydNco61DzdUsF-9ysqh8Gr8BasT0V9Btc9DRtYUqhk7wa8WiPwnvs3ko8MI_SHzLv_Q4rTaKkcAyM_3qNWi81AGYwXi8SgnGmX-lpISv3r0Y8ZguxfVJCSnuAqNUuCFwzYNWF053j3o9BGNQusQjv2_bLh5pIZJReF71EPHLmsV8rb1hOXQkOULQYHQqeE3gXh8gAGg==\" rel=\"nofollow noopener\" target=\"_blank\">meredith.kaya@apellis.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eimP88p8fm42oJ_WAz64dRAAW4SUB-bpPjM4dyTfy2nNTcI_t3-YgR9UkPKcDXxzQG_hpKARG-gCNBNjTe8zJwQvPWMthjxfNY3CsChc8TNxNhEDF3h58V4o0VAo2YFj3pRb7G1pmPQrC2t58Z7ykwG-KQtviFpjOA-bZWiYYd-znCyzwgPCp1U_I02kmKN3wx1FdqoDMIrKCPBPwb56dZNeuYmhTlYFixDYBrYSde56nygKuoOGkinDeGw1Scts09exZ-0LQvqymnUFsmIPhILn0nMdBgWYbMe1OBaS4A2VLfHF0Sl-GnRwX6-BRbEfts-6zPYCjO1cthczCv4vtBi9QRsIC3fn2vm57gE_BAYET2Gnl4dQZeWE0AFMPu7I\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a>617.599.8178<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YzBmMjdjNTQtM2ZkYi00NzgxLTlkMzktNDQzODE2M2NiNzQ1LTEwMzE1OTg=\/tiny\/Apellis-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals,\u00a0Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences: Citi Annual BioPharma Conference: Fireside chat on Wednesday, September 6, 2023, at 9:40 a.m. ET Wells Fargo Annual Healthcare Conference 2023: Fireside chat on Friday, September 8, 2023, at 9:30 a.m. ET The live conference webcasts will be posted on the \u201cEvents and Presentations\u201d page of the \u201cInvestors and Media\u201d section of the company\u2019s website. A replay of the webcasts will be available for approximately 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Apellis Pharmaceuticals to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780883","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals,\u00a0Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences: Citi Annual BioPharma Conference: Fireside chat on Wednesday, September 6, 2023, at 9:40 a.m. ET Wells Fargo Annual Healthcare Conference 2023: Fireside chat on Friday, September 8, 2023, at 9:30 a.m. ET The live conference webcasts will be posted on the \u201cEvents and Presentations\u201d page of the \u201cInvestors and Media\u201d section of the company\u2019s website. A replay of the webcasts will be available for approximately 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop &hellip; Continue reading &quot;Apellis Pharmaceuticals to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T11:37:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences\",\"datePublished\":\"2023-08-30T11:37:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/\"},\"wordCount\":220,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/\",\"name\":\"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=\",\"datePublished\":\"2023-08-30T11:37:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/","og_locale":"en_US","og_type":"article","og_title":"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals,\u00a0Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences: Citi Annual BioPharma Conference: Fireside chat on Wednesday, September 6, 2023, at 9:40 a.m. ET Wells Fargo Annual Healthcare Conference 2023: Fireside chat on Friday, September 8, 2023, at 9:30 a.m. ET The live conference webcasts will be posted on the \u201cEvents and Presentations\u201d page of the \u201cInvestors and Media\u201d section of the company\u2019s website. A replay of the webcasts will be available for approximately 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop &hellip; Continue reading \"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T11:37:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences","datePublished":"2023-08-30T11:37:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/"},"wordCount":220,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/","name":"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=","datePublished":"2023-08-30T11:37:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzOCM1Nzg5Mjk1IzIwMjAwMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apellis Pharmaceuticals to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780883"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780883\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}